Patients
hypersensitivity, ESCC, Cancer
CELIAC, METASTASIS, ESOPHAGUS CANCER, MALIGNANCIES, HYPERSENSITIVITY, CANCER
Patients’ inclusion criteria and the procedures of this prospective, single-center, randomized phase II trial have previously been reported. Eligible patients were aged between 18 and 70 years; had adequate bone marrow, hepatic, and renal function; a Karnofsky performance status (KPS) score ≥ 70; and had no history of other malignancies. Only patients with locally advanced (clinical stage II to IVA, including metastatic celiac or cervical nodes, according to the 6th edition of the American Joint Committee on Cancer [AJCC] staging system for esophagus cancer), histologically proven, and potentially curable ESCC, were eligible for inclusion. Primary exclusion criteria were the presence of distant metastasis (except for those confined to the celiac or cervical nodes) before treatment, a history of hypersensitivity to CDDP, 5-fluorouracil and docetaxel, and patients who were pregnant or breastfeeding. Our study protocol was reviewed by the SYSUCC Ethics Committee and approved. All patients gave their written informed consent to participate in the study.